09:00 AM EDT, 09/24/2024 (MT Newswires) -- Seelos Therapeutics ( SEEL ) said Tuesday its investigational ketamine-based treatment, SLS-002, was selected for inclusion in the US Department of Defense's Military and Veterans Adaptive Platform clinical trial of potential treatments for post-traumatic stress disorder.

The company said it signed a material transfer agreement with the US Army Medical Materiel Development Activity to supply SLS-002, or intranasal racemic ketamine, for the study and dosing of the SLS-002 group is expected to start before the end of the year. Financial details were not disclosed.

Seelos said SLS-002 is the only ketamine-based therapy included in the study.

Shares of the company were up more than 85% in recent Tuesday premarket activity.

Price: 0.3521, Change: +0.16, Percent Change: +85.32